Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Western Regional Medical Center

Status and phase: Withdrawn; Phase 2

Conditions: Metastatic Melanoma

Treatments: Drug: Cyclophosphamide and Interleukin 2

Study type: Interventional

Funder types: Other

Identifiers

NCT01833767

12-12

Details and patient eligibility

About

The purpose of this study is to determine response rates by administering low dose cyclophosphamide on day 1, followed by 5 days of outpatient IL2.

Full description

To determine the response rate, median duration of response and median survival of patients treated with this low-dose cyclophosphamide + moderate dose bolus Interleukin-2 schedule.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients must have a histologic diagnosis of metastatic melanoma. Patients may have received prior systemic therapy or may be previously untreated.
2. Patients must have measurable disease on physical exam or radiologic studies.
3. ECOG performance status of 0 or 1 and estimated survival of at least 3 months.
4. White blood count of > 3500/mm3, platelet count > 100,000/mm3, hemoglobin > 9.0 gm/dl; bilirubin, ALT, AST < 3 x upper limit of normal; serum creatinine < 2.0 mg/dl.
5. Patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. Patients with a positive stress test would be excluded from this trial.
6. Patients with elevated temperatures > 100.5 F must have sources of occult infection excluded.
7. Patients must be felt to have recovered from effects of prior therapy, such as > 2 weeks after prior chemotherapy.
8. Women of childbearing potential must have a negative pregnancy test and adequate precautions to prevent pregnancy during treatment must be taken.
9. Patient consent must be obtained prior to entrance onto study.

Exclusion criteria

• 1. Medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate.

  2. Autoimmune disease such as inflammatory arthritis which could be exacerbated by immune-based therapy.

  3. Prior history of psychiatric disorder which could be exacerbated by interleukin-2.

  4. Lactation or pregnancy.

  5. Evidence of significant cardiovascular disease including history of recent (< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional PVC's, angina, positive low-level stress test, or cerebrovascular accident.

  6. Current untreated brain metastasis.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Cyclophosphamide and Interleukin-2

Experimental group

Description:

Cytoxan IV on day 1, IL2 IV on days 1-5

Treatment:

Drug: Cyclophosphamide and Interleukin 2